keyword
MENU ▼
Read by QxMD icon Read
search

Corticosteroid use in copd

keyword
https://www.readbyqxmd.com/read/29785104/respiratory-medication-used-in-copd-patients-from-seven-latin-american-countries-the-lassyc-study
#1
Alejandro Casas, Maria Montes de Oca, Ana Mb Menezes, Fernando C Wehrmeister, Maria Victorina Lopez Varela, Laura Mendoza, Larissa Ramírez, Marc Miravitlles
Background: Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region. Methods: This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29785101/exacerbation-recovery-patterns-in-newly-diagnosed-or-maintenance-treatment-na%C3%A3-ve-patients-with-copd-secondary-analyses-of-ticari-1-trial-data
#2
David M Mannino, Emmanuelle M Clerisme-Beaty, Joanne Franceschina, Naitee Ting, Nancy K Leidy
Background: Little is known about the recovery patterns from acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in newly diagnosed or maintenance treatment-naïve patients with COPD. This study describes the course of AECOPD in these patients at the time of treatment for the symptoms of acute respiratory tract infection (RTI). Methods: This study was a secondary analysis of data from a 12-week, randomized clinical trial (TICARI 1) testing the efficacy and safety of once-daily tiotropium 18 µg maintenance therapy versus placebo in newly diagnosed or maintenance treatment-naïve COPD patients with acute RTI symptoms for ≤7 days...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29783858/effectiveness-and-safety-comparison-for-systemic-corticosteroid-therapy-with-and-without-inhaled-corticosteroids-for-copd-exacerbation-management
#3
Jordan A Pearce, Dane L Shiltz, Qian Ding
BACKGROUND: Only 1 small, single-center study has evaluated the combination of systemic plus inhaled corticosteroid (ICS) routes for chronic obstructive pulmonary disease (COPD) exacerbation management. This study aims to further improve the existing quantity and quality of evidence regarding the utility for combination therapy in the management of COPD exacerbation. OBJECTIVES: To evaluate length of hospital stay, readmission rate, incidence of infection, and mortality in hospitalized patients who experience a COPD exacerbation and receive systemic corticosteroid therapy with or without concurrent ICS...
May 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29773947/efficacy-safety-and-pharmacokinetics-of-budesonide-formoterol-fumarate-delivered-via-metered-dose-inhaler-using-innovative-co-suspension-delivery-technology-in-patients-with-moderate-to-severe-copd
#4
Edward M Kerwin, Thomas M Siler, Samir Arora, Patrick Darken, Earl Rose, Colin Reisner
Purpose: This study investigated the efficacy, safety, and pharmacokinetics of the inhaled corticosteroid/long-acting β2 -agonist fixed-dose combination budesonide/formoterol fumarate (BFF) metered dose inhaler (MDI), compared with the monocomponents budesonide (BD) MDI and formoterol fumarate (FF) MDI, in patients with moderate-to-severe COPD. Materials and methods: In this Phase IIb, randomized, double-blind, four-period, five-treatment, incomplete-block, crossover study (NCT02196077), all patients received BFF MDI 320/9...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29764749/prognosis-of-chronic-pulmonary-aspergillosis-in-patients-with-pulmonary-non-tuberculous-mycobacterial-disease
#5
Maiko Naito, Yu Kurahara, Shiomi Yoshida, Naoya Ikegami, Takehiko Kobayashi, Shojiro Minomo, Kazunobu Tachibana, Kazunari Tsuyuguchi, Seiji Hayashi, Katsuhiro Suzuki
BACKGROUND: Pulmonary non-tuberculous mycobacterial disease (PNTM) is a known risk factor for chronic pulmonary aspergillosis (CPA). However, few studies have focused on the prognosis of PNTM-associated CPA. In the present investigation, we aimed to elucidate the clinical course and prognostic factors of CPA in patients with PNTM. METHODS: We retrospectively investigated the medical records of 62 patients with CPA and a history of PNTM who were admitted to Kinki-chuo Chest Medical Center between 2010 and 2015...
May 11, 2018: Respiratory Investigation
https://www.readbyqxmd.com/read/29763411/characteristics-and-health-care-resource-use-of-subjects-with-copd-in-the-year-before-initiating-lama-monotherapy-or-lama-laba-combination-therapy-a-u-s-database-study
#6
Saurabh Nagar, Jeetvan Patel, Richard H Stanford
PURPOSE: To characterize subjects with chronic obstructive pulmonary disease (COPD) newly initiated on long-acting muscarinic antagonists (LAMA) or dual LAMA/long-acting β2-adrenergic agonist (LABA) therapy. DESIGN: This pilot/preliminary analysis was a retrospective crosssectional study of subjects with COPD from the Optum Impact National Managed Care Benchmark Database. METHODOLOGY: Subjects with at least one LAMA prescription in the index period (July 2008-June 2009) were included and stratified by treatment...
May 2018: Managed Care
https://www.readbyqxmd.com/read/29750142/single-inhaler-triple-therapy-in-symptomatic-copd-patients-fulfil-subgroup-analyses
#7
David M G Halpin, Ruby Birk, Noushin Brealey, Gerard J Criner, Mark T Dransfield, Emma Hilton, David A Lomas, Chang-Qing Zhu, David A Lipson
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2 -agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear. FULFIL, a phase III, randomised, double-blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62...
April 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29748063/-is-reduction-of-tobacco-consumption-associated-with-reduced-risk-of-cardiovascular-and-pulmonary-mortality-and-morbidity
#8
REVIEW
M Underner, G Peiffer, J Perriot, G Harika-Germaneau, N Jaafari
INTRODUCTION: Smokers without an intention to completely quit smoking often try to reduce their daily tobacco consumption. However, smoking reduction is not associated with reduced risk of all-cause mortality. The aim of this systematic literature review of data was to expose relations between reduction of daily tobacco consumption and a potential decrease in the risks of cardiovascular and pulmonary mortality and morbidity. METHOD: Medline, on the period 1980-2018 with the following keywords: "smoking reduction", "harm reduction", "mortality", "morbidity", "cardiovascular disease* ", myocardial infarction", "coronar* ", "stroke", "lung cancer", "COPD", "chronic obstructive pulmonary disease", "asthma", "pulmonary disease* " and "respiratory disease" limits "title/abstract"; the selected languages were English or French...
May 7, 2018: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/29747278/-the-associations-between-comorbidity-and-exacerbation-risk-in-patients-with-chronic-obstructive-pulmonary-disease
#9
Y L Huang, B Mao, J Mim, G H Li, Y Q Zheng, L H Wu, S J Wang, B Qu, J J Fu
Objective: To study the association between comorbidity and acute exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). Methods: This was a prospective cohort study with 64 stable COPD patients included. There were 64 males and 18 females with an average age of (68±9) years. Clinical characteristics, the number and type of comorbidities were recorded, and Charlson comorbidity index (CCI) was calculated. The patients were interviewed by phone calls every 3 months since baseline in which the number of acute exacerbations was recorded until 12 months...
May 12, 2018: Chinese Journal of Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29731926/practical-approach-to-lung-health-experience-from-the-republic-of-macedonia
#10
Biljana Ilievska-Poposka, Maja Zakoska, Stefan Talevski
BACKGROUND: Among the adults and children aged 5 yrs who attend PHC settings, 20-30% seeks to care for respiratory symptoms. Over 80-90% of the respiratory patients suffer from acute respiratory infections (ARI), followed by chronic obstructive pulmonary diseases (COPD), asthma, and less frequently with pneumonia and tuberculosis (TB). To improve the quality of care in patients who seek assistance for respiratory symptoms in PHC settings and the efficiency of respiratory service delivery within healthcare systems, WHO has designated several initiatives among which one is PAL (Practical Approach to Lung Health)...
April 15, 2018: Open Access Macedonian Journal of Medical Sciences
https://www.readbyqxmd.com/read/29724175/risk-and-impact-of-herpes-zoster-among-copd-patients-a-population-based-study-2009-2014
#11
Cintia Muñoz-Quiles, Mónica López-Lacort, Javier Díez-Domingo
BACKGROUND: The objective of this study was to assess the incidence of Herpes Zoster (HZ) among patients with chronic obstructive pulmonary disease (COPD) and the impact of HZ on the underlying COPD. METHODS: A retrospective cohort of all subjects older than 49 years was followed up between 2009 and 2014 using population and health databases of Valencia Region (Spain). HZ and COPD were identified using ICD-9 codes, differentiating COPD patients with inhaled corticosteroids prescriptions (COPD-ICS)...
May 3, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29719507/breathomics-for-assessing-the-effects-of-treatment-and-withdrawal-with-inhaled-beclomethasone-formoterol-in-patients-with-copd
#12
Paolo Montuschi, Giuseppe Santini, Nadia Mores, Alessia Vignoli, Francesco Macagno, Rugia Shoreh, Leonardo Tenori, Gina Zini, Leonello Fuso, Chiara Mondino, Corrado Di Natale, Arnaldo D'Amico, Claudio Luchinat, Peter J Barnes, Tim Higenbottam
Background: Prospective pharmacological studies on breathomics profiles in COPD patients have not been previously reported. We assessed the effects of treatment and withdrawal of an extrafine inhaled corticosteroid (ICS)-long-acting β2 -agonist (LABA) fixed dose combination (FDC) using a multidimensional classification model including breathomics. Methods: A pilot, proof-of-concept, pharmacological study was undertaken in 14 COPD patients on maintenance treatment with inhaled fluticasone propionate/salmeterol (500/50 μg b...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29719385/treatment-of-exacerbations-as-a-predictor-of-subsequent-outcomes-in-patients-with-copd
#13
Peter Ma Calverley, Antonio R Anzueto, Daniel Dusser, Achim Mueller, Norbert Metzdorf, Robert A Wise
Rationale: Exacerbations of COPD are managed differently, but whether treatment of one exacerbation predicts the likelihood of subsequent events is unknown. Objective: We examined whether the treatment given for exacerbations predicted subsequent outcomes. Methods: This was a post-hoc analysis of 17,135 patients with COPD from TIOtropium Safety and Performance In Respimat® (TIOSPIR® ). Patients treated with tiotropium with one or more moderate to severe exacerbations on study were analyzed using descriptive statistics, logistic and Cox regression analysis, and Kaplan-Meier plots...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29719383/differential-anti-inflammatory-effects-of-budesonide-and-a-p38-mapk-inhibitor-azd7624-on-copd-pulmonary-cells
#14
Andrew Higham, Pradeep Karur, Natalie Jackson, Danen M Cunoosamy, Paul Jansson, Dave Singh
Background: The effects of anti-inflammatory drugs in COPD patients may vary between different cell types. The aim of the current study was to assess the anti-inflammatory effects of the corticosteroid budesonide and a p38 MAPK inhibitor (AZD7624) on different cell types obtained from COPD patients and healthy controls. Methods: Eight healthy smokers, 16 COPD infrequent exacerbators, and 16 frequent COPD exacerbators (≥2 exacerbations in the last year) were recruited for bronchoscopy and blood sampling...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29713156/indacaterol-glycopyrronium-reduces-the-risk-of-clinically-important-deterioration-after-direct-switch-from-baseline-therapies-in-patients-with-moderate-copd-a-post-hoc-analysis-of-the-crystal-study
#15
Timm Greulich, Konstantinos Kostikas, Mina Gaga, Maryam Aalamian-Mattheis, Nadine S Lossi, Francesco Patalano, Xavier Nunez, Veronica A Pagano, Robert Fogel, Claus F Vogelmeier, Andreas Clemens
Purpose: COPD is a progressive disease characterized by exacerbations and a decline in health status and lung function. Clinically important deterioration (CID) is a composite endpoint used to evaluate treatment efficacy. This analysis evaluated the impact of a direct switch to once-daily indacaterol/glycopyrronium 110/50 µg (IND/GLY) from previous monotherapy with a long-acting β2 -agonist (LABA) or long-acting muscarinic antagonist (LAMA) or with an LABA and an inhaled corticosteroid (LABA + ICS) on reducing CID...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29705782/indacaterol-glycopyrronium-in-the-treatment-of-severe-respiratory-failure-marked-improvement-of-respiratory-failure-in-a-few-weeks-a-case-report
#16
Riccardo Pistelli, Maria Rosaria Castriotti, Loredana Panico
Chronic obstructive pulmonary disease is a highly prevalent disease, especially in the aging population, associated with several functional disabilities and a high economic burden. Dual bronchodilation with prefixed associations of long-acting β2-agonists and long-acting muscarinic antagonist have a significant role in the management of this condition. The newer combination, indacaterol/glycopyrronium, is useful as a once-a-day therapy and has proven superior to other treatment strategies including inhaled corticosteroids for improving symptoms and clinical condition with a very rapid effect...
2018: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/29696728/predictive-value-of-eosinophils-and-neutrophils-on-clinical-effects-of-ics-in-copd
#17
Floor J Hartjes, Judith M Vonk, Alen Faiz, Pieter S Hiemstra, Thérèse S Lapperre, Huib A M Kerstjens, Dirkje S Postma, Maarten van den Berge
BACKGROUND AND OBJECTIVE: Inflammation is present to a variable degree and composition in patients with COPD. This study investigates associations between both eosinophils and neutrophils in blood, sputum, airway wall biopsies and bronchoalveolar lavage (BAL) and their potential use as biomarkers for clinical response to inhaled corticosteroids (ICS). METHODS: In total, 114 steroid-naïve COPD patients of the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) study using ICS or placebo during 30-month follow-up were included...
April 26, 2018: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/29692381/current-status-of-community-acquired-pneumonia-in-patients-with-chronic-obstructive-pulmonary-disease
#18
REVIEW
De-Shun Liu, Xiu-Di Han, Xue-Dong Liu
Objective: Worldwide, community-acquired pneumonia (CAP) is a common infection that occurs in older adults, who may have pulmonary comorbidities, including chronic obstructive pulmonary disease (COPD). Although there have been clinical studies on the coexistence of CAP with COPD, there remain some controversial findings. This review presents the current status of COPD in CAP patients, including the disease burden, clinical characteristics, risk factors, microbial etiology, and antibiotic treatment...
May 5, 2018: Chinese Medical Journal
https://www.readbyqxmd.com/read/29679596/observational-studies-of-inhaled-corticosteroid-effectiveness-in-copd-lessons-learned
#19
Samy Suissa, Pierre Ernst
BACKGROUND: Randomized controlled trials at times investigate findings suggested by observational studies. For example, the TORCH trial, which did not show a mortality reduction with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD), was motivated by some observational studies that suggested considerable reductions in mortality with these drugs. Reasons for these discrepancies are unclear. METHODS: We searched the literature to identify all observational studies, including cohort and case-control studies, investigating the effectiveness of ICS on major outcomes in COPD patients, including death and hospitalization for COPD...
April 18, 2018: Chest
https://www.readbyqxmd.com/read/29653129/delivering-drugs-to-the-lungs-the-history-of-repurposing-in-the-treatment-of-respiratory-diseases
#20
Stephen P Newman
The repurposing of drug delivery by the pulmonary route has been applied to treatment and prophylaxis of an increasingly wide range of respiratory diseases. Repurposing has been most successful for the delivery of inhaled bronchodilators and corticosteroids in patients with asthma and chronic obstructive pulmonary disease (COPD). Repurposing utilizes the advantages that the pulmonary route offers in terms of more targeted delivery to the site of action, the use of smaller doses, and a lower incidence of side-effects...
April 11, 2018: Advanced Drug Delivery Reviews
keyword
keyword
66371
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"